A Modern Approach to the Treatment of Cancer, Mental Health, Pain and Other Serious Diseases

At EMulate Therapeutics™ we’re making targeted, non-invasive treatment a reality. Our technology has the potential to effectively treat cancer, mental health, pain and other diseases with few or no adverse effects. How is this possible?


Note: EMulate Therapeutics Voyager® ulRFE® system for GBM is an investigational medical device. Limited by United States law to investigational use only.

Founded in 2002 and headquartered in Seattle, WA, EMulate Therapeutics is a clinical-stage therapeutic device company. EMulate Therapeutics has invented and patented a groundbreaking technology that utilizes Radio Frequency Energy (RFE) precisely targeted at the ultra-low end of the RFE spectrum (ulRFE®) to specifically regulate signaling and metabolic pathways on the molecular and genetic levels – without chemicals, radiation or drugs – delivered via a simple-to-use non-invasive device called EMulate Therapeutics Voyager.

EMulate Therapeutics’ proprietary ulRFE technology is able to emulate the biological activity of a broad range of molecules including psychedelics, pain and chemotherapy drugs. EMulate Therapeutics is a clinical stage platform technology company developing non-invasive therapies delivered through a non-thermal, non-ionizing, wearable device, for treating numerous mental health conditions, as well as other serious ailments such as cancer, severe pain and other conditions affecting health. We currently possess 38 issued US and non-US patents to date, which will help support a long-term high margin business.

The company’s goal is to transform disease treatment on a global scale with ulRFE®. The proprietary technology has the potential to be applied to a wide range of conditions as well as veterinary medicine and non-medical applications.

EMulate Therapeutics’ clinical results have demonstrated encouraging clinical outcomes for the treatment of patients with brain cancer who are not well served by conventional standard of care therapies, which often result in poor outcomes and devastating side effects. Additional pre-clinical and clinical work is focused on exploring new applications in other oncology indications, pain management, mental health applications amongst others.

Scientific Platform

Our proprietary ultra-low Radio Frequency Energy (ulRFE) technology produces a targeted and specific energy field emulating a solvated molecule by measuring and recording their surface electrostatic surface potential as an oscillating magnetic field. The ulRFE energy field is delivered locally and non-systemically via a medical device. Pre-clinical and clinical studies suggest the ability to specifically modulate metabolic pathways and/or replicate known mechanisms of action for proven commercial drugs. To date, no adverse effects or toxicity related to the device have been observed in human clinical trials.

See Our Science